相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Preclinical assessment of an optimized AAV-FVIII vector in mice and non-human primates for the treatment of hemophilia A
Liron Elkouby et al.
MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2022)
BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression
Barbara A. Konkle et al.
BLOOD (2021)
Activated protein C has a regulatory role in factor VIII function
Amelia R. Wilhelm et al.
BLOOD (2021)
A long-term study of AAV gene therapy in dogs with hemophilia A identifies clonal expansions of transduced liver cells
Giang N. Nguyen et al.
NATURE BIOTECHNOLOGY (2021)
Factor VIII exhibits chaperone-dependent and glucose-regulated reversible amyloid formation in the endoplasmic reticulum
Juthakorn Poothong et al.
BLOOD (2020)
Human Immune Responses to Adeno-Associated Virus (AAV) Vectors
Giuseppe Ronzitti et al.
FRONTIERS IN IMMUNOLOGY (2020)
Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B
Lindsey A. George et al.
MOLECULAR THERAPY (2020)
Broader Implications of Progressive Liver Dysfunction and Lethal Sepsis in Two Boys following Systemic High-Dose AAV
Leon Morales et al.
MOLECULAR THERAPY (2020)
Etranacogene dezaparvovec (AMT-061 phase 2b): normal/near normal FIX activity and bleed cessation in hemophilia B
Annette Von Drygalski et al.
BLOOD ADVANCES (2019)
GO-8: Preliminary Results of a Phase I/II Dose Escalation Trial of Gene Therapy for Haemophilia a Using a Novel Human Factor VIII Variant
Amit C. Nathwani et al.
BLOOD (2018)
Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A
G. N. Nguyen et al.
JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2017)
Hemostatic agents of broad applicability produced by selective tuning of factor Xa zymogenicity
Lacramioara Ivanciu et al.
BLOOD (2015)
Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant
Jenny McIntosh et al.
BLOOD (2013)
Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
Matthew W. Bunce et al.
BLOOD (2011)
Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model
Denise E. Sabatino et al.
BLOOD (2009)
Directed Engineering of a High-expression Chimeric Transgene as a Strategy for Gene Therapy of Hemophilia A
Christopher B. Doering et al.
MOLECULAR THERAPY (2009)
Removal of B-domain sequences from factor V rather than specific proteolysis underlies the mechanism by which cofactor function is realized
R Toso et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Bioengineering of coagulation factor VIR for improved secretion
HZ Miao et al.
BLOOD (2004)
Factor VIII ectopically expressed in platelets: efficacy in hemophilia A treatment
HV Yarovoi et al.
BLOOD (2003)
High level expression of recombinant porcine coagulation factor VIII
CB Doering et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
分享论文
